This is a preview of subscription content, log in via an institution to check access.
Reference
Chouaid C, et al. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for first line treatment of advanced EGFR-Mutated Advanced Non-Small-Cell Lung Cancers. Journal of Thoracic Oncology : 24 Jul 2017
Rights and permissions
About this article
Cite this article
Afatinib cost effective for EGFRm+ NSCLC in France. PharmacoEcon Outcomes News 784, 8 (2017). https://doi.org/10.1007/s40274-017-4219-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4219-x